226 related articles for article (PubMed ID: 36952231)
41. Cabozantinib in combination with atezolizumab in patients with metastatic castration-resistant prostate cancer: results from an expansion cohort of a multicentre, open-label, phase 1b trial (COSMIC-021).
Agarwal N; McGregor B; Maughan BL; Dorff TB; Kelly W; Fang B; McKay RR; Singh P; Pagliaro L; Dreicer R; Srinivas S; Loriot Y; Vaishampayan U; Goel S; Curran D; Panneerselvam A; Schwickart M; Choueiri TK; Pal S
Lancet Oncol; 2022 Jul; 23(7):899-909. PubMed ID: 35690072
[TBL] [Abstract][Full Text] [Related]
42. Real-world outcomes of avelumab plus axitinib as first-line therapy in patients with advanced renal cell carcinoma in Japan: A multicenter, retrospective, observational study (J-DART).
Kato T; Nakano Y; Hongo F; Katano H; Miyagawa T; Ueda K; Azuma H; Nozawa M; Hinata N; Hori J; Otoshi T; Shimizu N; Aizawa M; Osada S; Matsui A; Oya M; Eto M; Tomita Y; Shinohara N; Uemura H
Int J Urol; 2024 Mar; 31(3):265-272. PubMed ID: 38110838
[TBL] [Abstract][Full Text] [Related]
43. Real-World Results of Cabozantinib Given as Alternative Schedule in Metastatic Renal Cell Carcinoma.
Bruchbacher A; Franke J; Alimohammadi A; Laukhtina E; Fajkovic H; Schmidinger M
Clin Genitourin Cancer; 2024 Apr; 22(2):98-108. PubMed ID: 37926597
[TBL] [Abstract][Full Text] [Related]
44. Avelumab in Combination with Eribulin Mesylate in Metastatic Urothelial Carcinoma: BTCRC GU-051, a Phase 1b Study.
Joshi M; Holder SL; Zhu J; Zheng H; Komanduri S; Warrick J; Yasin H; Garje R; Jia B; Drabick JJ; DeGraff DJ; Zakharia Y
Eur Urol Focus; 2022 Mar; 8(2):483-490. PubMed ID: 33741296
[TBL] [Abstract][Full Text] [Related]
45. Pamiparib in combination with tislelizumab in patients with advanced solid tumours: results from the dose-escalation stage of a multicentre, open-label, phase 1a/b trial.
Friedlander M; Meniawy T; Markman B; Mileshkin L; Harnett P; Millward M; Lundy J; Freimund A; Norris C; Mu S; Wu J; Paton V; Gao B
Lancet Oncol; 2019 Sep; 20(9):1306-1315. PubMed ID: 31378459
[TBL] [Abstract][Full Text] [Related]
46. First-line Immunotherapy-based Combinations for Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-analysis.
Quhal F; Mori K; Bruchbacher A; Resch I; Mostafaei H; Pradere B; Schuettfort VM; Laukhtina E; Egawa S; Fajkovic H; Remzi M; Shariat SF; Schmidinger M
Eur Urol Oncol; 2021 Oct; 4(5):755-765. PubMed ID: 33757737
[TBL] [Abstract][Full Text] [Related]
47. Immune checkpoint inhibitors combined with tyrosine kinase inhibitors or immunotherapy for treatment-naïve metastatic clear-cell renal cell carcinoma-A network meta-analysis. Focus on cabozantinib combined with nivolumab.
Niewada M; Macioch T; Konarska M; Mela A; Goszczyński A; Przekopińska B; Rajkiewicz K; Wysocki P; Krzakowski M
Front Pharmacol; 2022; 13():1063178. PubMed ID: 36937206
[No Abstract] [Full Text] [Related]
48. Camrelizumab (SHR-1210) alone or in combination with gemcitabine plus cisplatin for nasopharyngeal carcinoma: results from two single-arm, phase 1 trials.
Fang W; Yang Y; Ma Y; Hong S; Lin L; He X; Xiong J; Li P; Zhao H; Huang Y; Zhang Y; Chen L; Zhou N; Zhao Y; Hou X; Yang Q; Zhang L
Lancet Oncol; 2018 Oct; 19(10):1338-1350. PubMed ID: 30213452
[TBL] [Abstract][Full Text] [Related]
49. A Phase II Trial of Cabozantinib in Hormone Receptor-Positive Breast Cancer with Bone Metastases.
Xu J; Higgins MJ; Tolaney SM; Come SE; Smith MR; Fornier M; Mahmood U; Baselga J; Yeap BY; Chabner BA; Isakoff SJ
Oncologist; 2020 Aug; 25(8):652-660. PubMed ID: 32463152
[TBL] [Abstract][Full Text] [Related]
50. Avelumab in unresectable/metastatic, progressive, grade 2-3 neuroendocrine neoplasms (NENs): Combined results from NET-001 and NET-002 trials.
Chan DL; Rodriguez-Freixinos V; Doherty M; Wasson K; Iscoe N; Raskin W; Hallet J; Myrehaug S; Law C; Thawer A; Nguyen K; Singh S
Eur J Cancer; 2022 Jul; 169():74-81. PubMed ID: 35504244
[TBL] [Abstract][Full Text] [Related]
51. Cabozantinib for the treatment of patients with metastatic non-clear cell renal cell carcinoma: A retrospective analysis.
Campbell MT; Bilen MA; Shah AY; Lemke E; Jonasch E; Venkatesan AM; Altinmakas E; Duran C; Msaouel P; Tannir NM
Eur J Cancer; 2018 Nov; 104():188-194. PubMed ID: 30380460
[TBL] [Abstract][Full Text] [Related]
52. A phase 2 randomised discontinuation trial of cabozantinib in patients with ovarian carcinoma.
Vergote IB; Smith DC; Berger R; Kurzrock R; Vogelzang NJ; Sella A; Wheler J; Lee Y; Foster PG; Weitzman R; Buckanovich RJ
Eur J Cancer; 2017 Sep; 83():229-236. PubMed ID: 28755607
[TBL] [Abstract][Full Text] [Related]
53. Cabozantinib with immune checkpoint inhibitor versus cabozantinib monotherapy in patients with metastatic clear cell renal cell carcinoma progressing after prior immune checkpoint inhibitor.
Gebrael G; Jo Y; Mathew Thomas V; Li H; Sayegh N; Tripathi N; Srivastava A; Nordblad B; Dal E; Narang A; Brundage J; Campbell P; Galarza Fortuna G; Hage Chehade C; Maughan BL; Agarwal N; Swami U
Cancer; 2024 Apr; ():. PubMed ID: 38564301
[TBL] [Abstract][Full Text] [Related]
54. Avelumab Plus Intermittent Axitinib in Previously Untreated Patients with Metastatic Renal Cell Carcinoma. The Tide-A Phase 2 Study.
Iacovelli R; Ciccarese C; Buti S; Zucali PA; Fantinel E; Bimbatti D; Verzoni E; Accettura C; Bonomi L; Buttigliero C; Fornarini G; Pipitone S; Atzori F; Masini C; Massari F; Primi F; Strusi A; Giudice GC; Perrino M; Maruzzo M; Milella M; Giannarelli D; Brunelli M; Procopio G; Tortora G
Eur Urol; 2024 Mar; ():. PubMed ID: 38521617
[TBL] [Abstract][Full Text] [Related]
55. Avelumab or talazoparib in combination with binimetinib in metastatic pancreatic ductal adenocarcinoma: dose-finding results from phase Ib of the JAVELIN PARP MEKi trial.
Rodon Ahnert J; Tan DS; Garrido-Laguna I; Harb W; Bessudo A; Beck JT; Rottey S; Bahary N; Kotecki N; Zhu Z; Deng S; Kowalski K; Wei C; Pathan N; Laliberte RJ; Messersmith WA
ESMO Open; 2023 Aug; 8(4):101584. PubMed ID: 37379764
[TBL] [Abstract][Full Text] [Related]
56. Phase II Clinical Trial of Axitinib and Avelumab in Patients With Recurrent/Metastatic Adenoid Cystic Carcinoma.
Ferrarotto R; Sousa LG; Feng L; Mott F; Blumenschein G; Altan M; Bell D; Bonini F; Li K; Marques-Piubelli ML; Dal Lago EA; Johnson JJ; Mitani Y; Godoy M; Lee A; Kupferman M; Hanna E; Glisson BS; Elamin Y; El-Naggar A
J Clin Oncol; 2023 May; 41(15):2843-2851. PubMed ID: 36898078
[TBL] [Abstract][Full Text] [Related]
57. Avelumab in patients with previously treated metastatic adrenocortical carcinoma: phase 1b results from the JAVELIN solid tumor trial.
Le Tourneau C; Hoimes C; Zarwan C; Wong DJ; Bauer S; Claus R; Wermke M; Hariharan S; von Heydebreck A; Kasturi V; Chand V; Gulley JL
J Immunother Cancer; 2018 Oct; 6(1):111. PubMed ID: 30348224
[TBL] [Abstract][Full Text] [Related]
58. Analysis of Toxicity and Clinical Outcomes in Full Versus Reduced Starting Dose Cabozantinib in Metastatic Renal Cell Carcinoma Patients.
Martini DJ; Evans ST; Liu Y; Shabto JM; Uner OE; Olsen TA; Brown JT; Russler GA; Yantorni L; Caulfield S; Goldman JM; Nazha B; Harris WB; Master VA; Kucuk O; Carthon BC; Bilen MA
Clin Genitourin Cancer; 2022 Feb; 20(1):53-59. PubMed ID: 34922840
[TBL] [Abstract][Full Text] [Related]
59. First-line Treatment of Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-analysis.
Hahn AW; Klaassen Z; Agarwal N; Haaland B; Esther J; Ye XY; Wang X; Pal SK; Wallis CJD
Eur Urol Oncol; 2019 Nov; 2(6):708-715. PubMed ID: 31588018
[TBL] [Abstract][Full Text] [Related]
60. Efficacy and tolerability of anti-programmed death-ligand 1 (PD-L1) antibody (Avelumab) treatment in advanced thymoma.
Rajan A; Heery CR; Thomas A; Mammen AL; Perry S; O'Sullivan Coyne G; Guha U; Berman A; Szabo E; Madan RA; Ballester LY; Pittaluga S; Donahue RN; Tsai YT; Lepone LM; Chin K; Ginty F; Sood A; Hewitt SM; Schlom J; Hassan R; Gulley JL
J Immunother Cancer; 2019 Oct; 7(1):269. PubMed ID: 31639039
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]